T. Rowe Price Associates’s Kymera Therapeutics KYMR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $299M | Buy |
6,859,202
+156,752
| +2% | +$6.84M | 0.03% | 354 |
|
|
2025
Q1 | $183M | Sell |
6,702,450
-167,883
| -2% | -$4.6M | 0.02% | 442 |
|
|
2024
Q4 | $276M | Buy |
6,870,333
+224,859
| +3% | +$9.05M | 0.03% | 367 |
|
|
2024
Q3 | $315M | Buy |
6,645,474
+254,816
| +4% | +$12.1M | 0.04% | 353 |
|
|
2024
Q2 | $191M | Buy |
6,390,658
+58,646
| +0.9% | +$1.75M | 0.02% | 425 |
|
|
2024
Q1 | $255M | Buy |
6,332,012
+996,300
| +19% | +$40.1M | 0.03% | 381 |
|
|
2023
Q4 | $136M | Buy |
5,335,712
+278,287
| +6% | +$7.09M | 0.02% | 489 |
|
|
2023
Q3 | $70.3M | Buy |
5,057,425
+50,277
| +1% | +$699K | 0.01% | 585 |
|
|
2023
Q2 | $115M | Buy |
5,007,148
+340,467
| +7% | +$7.83M | 0.02% | 499 |
|
|
2023
Q1 | $138M | Buy |
4,666,681
+287,522
| +7% | +$8.52M | 0.02% | 458 |
|
|
2022
Q4 | $109M | Buy |
4,379,159
+281,447
| +7% | +$7.02M | 0.02% | 473 |
|
|
2022
Q3 | $89.2M | Sell |
4,097,712
-1,126,974
| -22% | -$24.5M | 0.01% | 507 |
|
|
2022
Q2 | $103M | Buy |
5,224,686
+1,329,481
| +34% | +$26.2M | 0.01% | 650 |
|
|
2022
Q1 | $165M | Buy |
3,895,205
+344,677
| +10% | +$14.6M | 0.02% | 589 |
|
|
2021
Q4 | $225M | Buy |
3,550,528
+317,331
| +10% | +$20.1M | 0.02% | 528 |
|
|
2021
Q3 | $190M | Buy |
3,233,197
+1,388,271
| +75% | +$81.5M | 0.02% | 561 |
|
|
2021
Q2 | $89.5M | Buy |
1,844,926
+911,948
| +98% | +$44.2M | 0.01% | 826 |
|
|
2021
Q1 | $36.3M | Buy |
932,978
+540,902
| +138% | +$21M | ﹤0.01% | 1113 |
|
|
2020
Q4 | $24.3M | Buy |
392,076
+97,381
| +33% | +$6.04M | ﹤0.01% | 1172 |
|
|
2020
Q3 | $9.52M | Buy |
+294,695
| New | +$9.52M | ﹤0.01% | 1311 |
|